Booking
On November 14 last year, the EMA recommended approval of lecanemab for Alzheimer's disease in the EU. Despite this, it is taking a long time for the drugs to reach Sweden, while thousands of patients in the US are being treated with this particular Swedish-made drug. How can it be so different? What effects have been seen from the treatment in the US?
At the same time, there are concerns about whether the healthcare system will be able to cope with an influx of patients when the medicine becomes available, and how to triage and select early on who should receive the medicine and who should not.
Professor Henrik Zetterberg is one of our most internationally renowned researchers, leading the development of the new generation of blood biomarker diagnostics.
In this lecture, he will take us through the future of diagnostics, the future of treatments, how it can differ so much on two sides of the Atlantic and what challenges we will soon face...
Time of the webinar: Thursday, November 13, 12-13.
Register for the webinar: Click here
A warm welcome!
